OTCMKTS:GTSIF Lobe Sciences (GTSIF) Stock Price, News & Analysis → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free GTSIF Stock Alerts $0.01 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.0115▼$0.014550-Day Range$0.0014▼$0.018052-Week Range$0.03▼$0.22Volume3,561 shsAverage Volume595,549 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Lobe Sciences alerts: Email Address Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About Lobe Sciences Stock (OTCMKTS:GTSIF)Lobe Sciences Ltd., a technology and services company, provides real estate, financial, management, intellectual property, and branding support for development of transformational medicine in the United States. The company intends to develop psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications. It also owns acquired brands, intellectual property, and leases office and production premises to a cannabis processor and retailer. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.Read More GTSIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTSIF Stock News HeadlinesMay 5, 2023 | finance.yahoo.comLobe Sciences, Ltd. Provides Update on VitamindApril 21, 2023 | benzinga.comLobe Sciences Stock (OTC:LOBEF), DividendsMarch 11, 2023 | finance.yahoo.comChronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!February 23, 2023 | proactiveinvestors.comLobe Sciences to advance two new chemical entities through exclusive agreement with Quality Chemical LaboratoriesJanuary 26, 2023 | benzinga.comLobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board FeesNovember 8, 2022 | finance.yahoo.comLobe Sciences Ltd. (LOBE.CN)June 16, 2022 | finance.yahoo.comLobe Sciences Announces Roadmap for Remainder of 2022 and Early 2023March 30, 2022 | proactiveinvestors.comLobe Sciences plans to advance to Phase 1 PTSD study in second half of 2022 with psilocybin and NACDecember 10, 2021 | finance.yahoo.comLobe Sciences Ltd. (LOBEF)November 15, 2021 | finance.yahoo.comLobe Sciences Announces Common Stock to Trade Under the Symbol "LOBEF" in US MarketsNovember 8, 2021 | finance.yahoo.comLobe Sciences Invites You to Join Us at the Q4 Virtual Investor SummitOctober 6, 2021 | finance.yahoo.comLobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of AdvisorsOctober 5, 2021 | finance.yahoo.comLobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor ConferencesOctober 4, 2021 | finance.yahoo.comLobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSDSeptember 28, 2021 | finance.yahoo.comLobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSDSeptember 27, 2021 | finance.yahoo.comLobe Sciences to Present at the Benzinga Healthcare Small Cap ConferenceSeptember 16, 2021 | finanznachrichten.deLobe Sciences Ltd.: Lobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics ConferenceSeptember 15, 2021 | finance.yahoo.comLobe Sciences to Participate at the Advances in Mental Health Psychedelics and Non-Psychedelics ConferenceSeptember 13, 2021 | finance.yahoo.comLobe Sciences Provides Corporate Update to Investors and StakeholdersSeptember 10, 2021 | finance.yahoo.comLobe Sciences to Present At H.C. Wainwright 23rd Annual Global Investment ConferenceAugust 25, 2021 | yahoo.comBeyoncé Channeled Audrey Hepburn in a Chic LBD and 128.54 Carat "Tiffany Diamond" NecklaceAugust 23, 2021 | finance.yahoo.comLobe Sciences Appoints Albert "Skip" Rizzo, Ph.D to Scientific Advisory BoardSee More Headlines Receive GTSIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lobe Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:GTSIF CUSIPN/A CIKN/A Webwww.greenstarbiosciences.com Phone604-834-9499FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jonathan R. Gilbert (Age 50)Exec. Chairman Mr. Philip J. Young (Age 64)CEO, Corp. Sec. & Director Mr. Brian ZasitkoChief Financial OfficerMr. Daniel S. McAtee (Age 55)Chief Operating Officer Mr. Maghsoud Dariani (Age 68)Chief Science Officer Key Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors GTSIF Stock Analysis - Frequently Asked Questions How have GTSIF shares performed in 2024? Lobe Sciences' stock was trading at $0.0120 at the beginning of the year. Since then, GTSIF stock has increased by 20.8% and is now trading at $0.0145. View the best growth stocks for 2024 here. How do I buy shares of Lobe Sciences? Shares of GTSIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GTSIF) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lobe Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
